Type 2 diabetes and the risk of mortality among patients with prostate cancer

Cancer Causes and Control

Volumn 25, Issue 3, 2014, Pages 329-338

  Bensimon, Leah ^a,b   Yin, Hui ^a   Suissa, Samy ^a,b   Pollak, Michael N ^b   Azoulay, Laurent ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hazard ratios; Mortality; Prostate cancer; Type 2 diabetes

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FACTUAL DATABASE; FOLLOW UP; HUMAN; HYPERINSULINEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SMOKING;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84895539904     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0334-6     Document Type: Article

References (27)

1. Chowdhury TA (2010) Diabetes and cancer. QJM 103(12):905-915
2. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398-1403
3. Yeap BB, Alfonso H, Chubb SA et al (2012) Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 97(11):4030-4039
4. Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR (2005) History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 16(7):789-797
5. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH (2010) Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 77(5):1329-1337
6. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76(5):1240-1244
7. Tseng CH (2011) Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men. Ann Med 43(2):142-150
8. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K (2012) The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 118(5):1353-1361
9. Shetti MB, Merrick GS, Butler WM et al (2012) The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Am J Clin Oncol 35(6):572-579
10. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL (2012) A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 35(1):113-118
11. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299-304
12. Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45(5):419-425
13. Read codes. United Kingdom National Health Service. http://www. connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes. Accessed 30 Dec 2013
14. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302(6779):766-768
15. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21(3):299-304
16. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49(6):591-596
17. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686-689
18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69(1):4-14
19. Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81(3):515-526
20. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P (2013) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 16(2):151-158 S1
21. Venkateswaran V, Haddad AQ, Fleshner NE et al (2007) Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99(23):1793-1800
22. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039-1047
23. Lubik AA, Gunter JH, Hendy SC et al (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71(17):5754-5764
24. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159-169
25. Jones ME, Swerdlow AJ (1998) Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol 148(10):1012-1017
26. Schatzkin A, Slud E (1989) Competing risks bias arising from an omitted risk factor. Am J Epidemiol 129(4):850-856
27. Albertsen PC, Walters S, Hanley JA (2000) A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 163(2):519-523